This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Optimer Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those projected in the forward-looking statements. Examples of such risks and uncertainties include whether Optimer and its partners will be able to drive further adoption in sales of DIFICID, including in new markets and territories, whether Optimer's lifecycle management initiatives will ultimately result in label expansion, risks involved in the regulatory approval process, and the uncertainty in forecasting future cash requirements and financial results.

For a full disclosure of these risks and uncertainties, please review Optimer's annual report on Form 10-K and subsequent quarterly reports on Form 10-Q as filed with the U.S. Securities and Exchange Commission.

Furthermore, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, July 31, 2012. Optimer undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. This conference call is also being webcast and will be archived on our website for 30 days after today.

Earlier today, we released financial results for the second quarter ended June 30, 2012. If you've not received this news release, or if you'd like to be added to the company's distribution list, please visit the Investor Section of our website at

I would now like to turn the call over to Pedro Lichtinger, Optimer's President and CEO.

Pedro Lichtinger

Thank you, David. July 18 mark the one year anniversary of the launch of DIFICID, and we're very proud of our accomplishments. From launch last year, to the end of June, we achieved $51.1 million in net sales and shipped almost 20,000 treatments. We surpassed our 12-month sales gross established with Cubist. And so, Cubist has earned a $5 million bonus payment and a portion of the gross margin above that threshold.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.70 -0.60%
FB $101.91 0.90%
GOOG $683.11 -0.15%
TSLA $150.47 4.73%
YHOO $26.76 -1.25%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs